H.C. Wainwright Initiates a Buy Rating on ADMA Biologics (ADMA)

ADMA Biologics (ADMA) received a Buy rating and a $10 price target from H.C. Wainwright analyst Ram Selvaraju on February 7. The company’s shares closed on Friday at $2.77, close to its 52-week low of $2.08.

Selvaraju observed:

“We value ADMA via discounted cash flow (DCF)-based analysis, which models four principal lines of business (Nabi-HB, plasma reselling from its own plasma center, BIVIGAM and RI-002). We apply a 10% discount rate and 30% effective tax rate, along with a 2.5% terminal growth rate.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 30.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADMA Biologics with a $11.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.96 and a one-year low of $2.08. Currently, ADMA Biologics has an average volume of 310.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.